AZD8931, an Equipotent, Reversible Inhibitor of Signaling...

Clinical Cancer Research 2010 / 02 Vol. 16; Iss. 4

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Hickinson, D. M., Klinowska, T., Speake, G., Vincent, J., Trigwell, C., Anderton, J., Beck, S., Marshall, G., Davenport, S., Callis, R., Mills, E., Grosios, K., Smith, P., Barlaam, B., Wilkinson, R. W
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
16
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.ccr-09-2353
Date:
February, 2010
File:
PDF, 880 KB
english, 2010
Conversion to is in progress
Conversion to is failed